Vaso (VASO) AI Stock Analysis

• Market Cap: $21.70M
• Dividend Yield: N/A
• Average Volume (3M): 63.84K
• Price to Earnings (P/E): 20.8
• Beta (1Y): 0.14
• Revenue Growth: 8.63%
• EPS Growth: -67.03%
• Country: US
• Employees: 298
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 175,741,320
• 10 Day Avg. Volume: 29,707
• 30 Day Avg. Volume: 63,843
• PEG Ratio: -0.34
• Price to Book (P/B): 0.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 5.66
• Enterprise Value/Market Cap: -0.01
• Enterprise Value/Revenue: >-0.01
• Enterprise Value/Gross Profit: >-0.01
• Enterprise Value/Ebitda: -0.04
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 72 Outperform
• Price Target: $0.00 ▼(-100.00%Downside)

Vaso's overall stock score reflects a strong financial performance with robust cash flow and low leverage, despite room for profitability improvement. The technical analysis shows mixed signals, with neutral to slightly positive momentum. The valuation suggests moderate investor expectations, balanced by the lack of a dividend yield.

Vaso Business Overview & Revenue Model

Company Description

Vaso Corporation (VASO) is a diversified medical technology company that operates primarily within the healthcare and information technology sectors. The company is known for its advanced medical devices, diagnostic imaging equipment, and healthcare information technology solutions. Vaso focuses on delivering innovative technologies and services aimed at improving patient care and enhancing operational efficiencies for healthcare providers.

How the Company Makes Money

Vaso Corporation generates revenue through multiple streams. Its primary income is derived from the sale and service of medical devices and diagnostic imaging equipment. Additionally, Vaso earns revenue through its healthcare information technology solutions, which include software and services designed to optimize healthcare operations and improve patient outcomes. The company also benefits from strategic partnerships and collaborations with other technology and healthcare organizations, which help to expand its product offerings and market reach, thus contributing to its overall earnings.

Vaso Financial Statement Overview

Summary

Vaso demonstrates a strong financial position with steady revenue growth and a robust balance sheet characterized by low leverage. While profitability metrics indicate room for improvement, the company's cash flow performance is commendable, highlighting its ability to generate cash efficiently. Overall, Vaso is well-positioned for future growth, with potential to enhance profitability.

Income Statement

Vaso shows a solid performance with steady revenue growth, achieving a 7.98% increase from 2023 to the TTM. The gross profit margin is healthy at 59.98% for TTM, indicating efficient cost management. However, the net profit margin is relatively low at 1.20% in TTM, and EBIT margin is only 0.74%, suggesting room for profitability improvement. EBITDA margin at 2.13% for TTM also points to moderate operational efficiency.

Balance Sheet

Vaso's balance sheet is strong, with a low debt-to-equity ratio of 0.08 in TTM, indicating minimal leverage and financial risk. The equity ratio of 34.20% shows a stable financial structure. The ROE is modest at 3.94% in TTM, reflecting moderate returns on investments made by shareholders.

Cash Flow

Vaso's cash flow is robust, with free cash flow showing significant growth of 120.76% from 2023 to TTM. The operating cash flow to net income ratio is favorable at 3.61 for TTM, suggesting efficient cash generation relative to net income. The free cash flow to net income ratio is also strong at 3.85, indicating good cash conversion efficiency.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
87.49M	86.77M	81.02M	80.02M	75.58M	69.85M
	Gross Profit
52.49M	52.05M	50.59M	48.48M	43.13M	38.57M
	EBIT
645.00K	285.00K	4.20M	7.03M	2.82M	772.00K
	EBITDA
1.86M	2.10M	5.95M	8.38M	6.66M	3.23M
	Net Income Common Stockholders
1.05M	951.00K	4.80M	11.87M	6.10M	358.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
25.32M	26.27M	25.32M	20.32M	6.65M	7.58M
	Total Assets
75.76M	82.94M	75.76M	72.66M	52.36M	50.38M
	Total Debt
2.06M	2.38M	2.06M	1.81M	1.39M	13.19M
	Net Debt
-9.28M	-23.90M	-9.28M	-10.01M	-4.64M	6.38M
	Total Liabilities
48.91M	55.24M	48.91M	49.78M	41.05M	45.29M
	Stockholders Equity
26.84M	27.70M	26.84M	22.88M	11.31M	5.08M
Cash Flow		Free Cash Flow
4.04M	1.83M	4.57M	13.85M	7.40M	4.93M
	Operating Cash Flow
3.79M	3.28M	5.30M	14.42M	7.82M	5.93M
	Investing Cash Flow
2.22M	11.73M	-5.66M	-8.42M	-260.00K	-575.00K
	Financing Cash Flow
-237.00K	-89.00K	-134.00K	-230.00K	-8.33M	-553.00K

Vaso Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VASO, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.13, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.83 is Neutral, neither overbought nor oversold. The STOCH value of 6.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VASO.

Vaso Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VASO	72 Outperform	$21.70M	20.85	4.02%	―	8.63%	-67.03%
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
VSEE	46 Neutral	$16.60M	―	-3190.66%	―	―	-806.84%
ZCMD	43 Neutral	$30.81M	―	-3.31%	―	-18.37%	71.61%
MSPR	40 Neutral	$11.87M	―	-458.99%	―	34.74%	-53.67%

Vaso Corporate Events

Vaso Announces Major Management Changes for 2025

Vaso announced significant management changes effective January 1, 2025. Jane Moen has been appointed as the Chief Operating Officer, while Peter C. Castle will remain as President of VasoTechnology, Inc. Michael Beecher steps down as Co-Chief Financial Officer and Secretary, with Jonathan Newton assuming the role of Chief Financial Officer, Treasurer, and Secretary.